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assaying hepatitis Be antigen (HBeAg), antibody to
HBeAg (anti-HBe) and viral DNA. Positvity of these
markers could be significant in the determination of
subjects that would require antiviral therapy . Values
between 11.9%- 23.1% of HBeAg have been reported
among Nigerian patients with chronic liver diseases
but there are no data on anti-HBe. Furthermore,
scarcity of facilities for detailed assay of HBV
serological markers in Nigeria could lead to the
institution of antiviral therapy in some patients with
chronic hepatitis B infection once they are discovered
to be HBsAg sero-positive. In order to reduce these
possible pitfalls in the diagnosis and treatment of
HBV infection among Nigerians, we present the
result of our study comparing sero-assays for HBsAg
by HMA, GWHB and ELISA. In addition, we report
the results of sero-analysis of HBeAg and anti-HBe
in Nigerian patients that are HBsAg sero-positive by
ELISA.
Fifty-five Nigerian adult patients who
consented to participate in the study had their blood




Comparison of HMAwith ELISAin the sero-assay
of HBsAg:
INTRODUCTION
Hepatitis B virus occurs globally although with
varying sero-prevalence rates in different regions
and countries . In Nigeria, just as in other African
countries, it is endemic causing significant morbidity
and mortality . Although, the virus has many
serological markers for its detection , the most
commonly assayed marker is the hepatitis B surface
antigen (HBsAg). However, various methods of
sero-detection of HBsAg are available, each with
different sensitivity, specificity, cost and technology
of assay . For routine diagnosis of HBV infection
among Nigerians, both Haemaglutination Method
(HMA) and Enzyme linked immunoassay (ELISA)
are commonly utilized. These practices give rise to
varying prevalence rates of the infection among the
population because of the differences in the
specificity and sensitivity of the diagnostic tests. A
commonly used rapid test for HBsAg detection is
Glaxo Welcome HB rapid test kit (GWHB) -
AMRAD ICT,Australia.





Correspondence: Dr S O Ola
E-Mail:sooa2001@ yahoo.com
350
Nigerian Journal of Clinical Practice
December 2009 Vol. 12(4):350-354
PITFALLS IN DIAGNOSIS OF HEPATITIS B VIRUS INFECTION AMONG
ADULTS NIGERIANS
*SO Ola, *JA Otegbayo, *A Yakubu, *AO Aje, GN Odaibo, ***W Shokunbi**
Department of *Medicine, **Virology and ***Haematology, College of Medicine, University of Ibadan;







Hepatitis B virus infection is common in Nigerians and its diagnosis is necessary for effective
treatment and eradication. This study is aimed at highlighting the serological factors jeopardizing the diagnosis
and treatment of the infection among Nigerians adults.
Three studies were carried out. The first study involved 56 Nigerian adults and it
compared the assay of HBsAg by Haemagulation Method (HMA) with Enzyme linked immunoassay (ELISA).
The second study was a comparison of Glaxo Welcome HB rapid test(GWHB) with ELISA in sero-assay of
HBsAg and HBeAg among 25 Nigerian subjects while the third study was on the assay of the sera of HBsAg
positive patients for HBeAg and anti-HBe in forty two Nigerian patients by ELISA.
The sero - prevalence rates of HBsAg were 41.8% and 61.8% by HM and ELISA respectively with
false HBsAg sero-positives and sero-negatives by HM of 5.4% and 25.5% respectively. Similarly, there was
sero-detection of HBsAg in 84% and 80% by ELISA and GWHB respectively in 25 Nigerian adults. In
addition, 19% and 64% of the 42 patients with HBsAg sero-positivity were also positive for HBeAg and anti-
HBe respectively, while 31% of the patients were both HBeAg and anti-HBe sero-negative.
Sero-diagnosis of HBsAg and other serological markers of infectivity in patients with HBV
should be carried out by ELISA rather than HMA among adult Nigerians. Furthermore, high infectivity of the
virus abounds among Nigerian with HBV infection.
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Kit, UK) and ELISA (Wellcozyme Kit Murex, UK)
at the Blood Bank of the Department of
Haematology and Virology Department, University
College Hospital, Ibadan, Nigeria; respectively.
Twenty-five
consecutive Nigerian subjects (18 males and 7
females) attending the Medical Clinic of the
University College Hospital, Ibadan, Nigeria were
studied. Whole blood specimens collected by
capillary tube of the test kits were assayed
consecutively for HBsAg and HBeAg following the
manufacturer's protocol. Results were read
immediately and recorded. Blood taken at the same
time of assay by GWHB were also analysed for
HBsAg by ELISA.
Forty-two Nigerian patients
who were HBsAg sero-positive by ELISA had their
sera tested for HBeAg and anti-HBe using ELISA
technique. The ethical approval was sought and
obtained from the Joint UI/UCH Ethical Review
Board. Results of all the assays including
calculations for sensitivity, specificity, Positive and
Negative Predictive Values were documented, and
the data were analysed using appropriate statistical
instruments with significant difference specified at p
< 0.05.
The subjects studied for assay of HBsAg by HMA
and ELISA consisted of 14 healthy adults, 13
patients with chronic hepatitis and 14 patients each
with liver cirrhosis and hepatocellular carcinoma.
The sero prevalence rates of HBsAg in all the
subjects were 41.8% and 61.8% by HMA and
ELISArespectively (x = 4.41 P< 0.05).
Comparison of the Product # GWHB rapid test
with ELISA in sero-assay of HBsAg:




False HBsAg sero-positives and sero-negatives by
HMA compared to ELISA were 5.4% and 25.5%
respectively (Table I). There was no gender
difference in the sero prevalence rates of HBsAg by
either HMA or ELISA. Comparing sero assay of
HBsAg by HMA with ELISA, HMA gave sensitivity,
specificity, positive and negative predictive values of
59% , 86% , 87% and 56% respectively. This showed
that sero-assay of HBsAg by ELISA was a better
diagnostic method than HM (Mc Nemar test, x =
7.116, P< 0.01).
There was sero-detection of HBsAg in 84% and 80%
by ELISA and GWHB respectively in 25 subjects
studied, Table 2. False negative result was 4% by
GWHB when compared with ELISA and the
sensitivity, specificity, positive and negative
predictive values were 95%, 100%, 100% and 80%
respectively. The HBeAg was not detected in any
subject by GWHB. Table 3 shows that 19% and 64%
of the 42 patients with HBsAg sero-positivity were
also positive for HBeAg and anti-HBe respectively.
Furthermore, 14% and 31% of the patients were Sero-
positive and negative respectively for both HBeAg
and anti-HBe. In addition, 69% of the patients were
sero-positive for HBeAg and / or, anti-HBe.
Table 4 shows that HBsAg sero-positive subjects in
all the three studied subgroups had a male : female
ratio of about 3:1 and their distribution spread
through the different adult age groups irrespective of
their genders differences.
2
Table 1: Assay of HBsAg by ELISA and Haemaglutination Method in Nigerian Adults.
ELISA
H M A - H a e m a g l u t i n a t i o n M e t h o d
E L I S A - E n z y m e L i n k e d I m m u n o a s s a y
P P V - P o s i t i v e P r e d i c t i v e V a l u e
N P V - N e g a t i v e P r e d i c t i v e V a l u e
HMA versus ELISA (Mc Nemar test) X =7.186, p<0.012
Table 4: Age Distribution in all HBsAg Sero-positive NigerianAdults by ELISA.
Age (years) A B C Male Female
20 2 3 6 9 2 11 (9.0)
21-30 12 6 19 29 8 37 (30.3)
31-40 11 6 7 18 6 24 (19.7)
41-50 8 4 2 11 3 14 (11.5)
51-60 16 6 6 21 7 28 (23.0)
>60 6 - 2 5 3 8 (6.5)
SUBJECTS SEX Total (%)






= Comparison of haemaglutination method with ELISAin the sero-assay of HBsAg
= Comparison of the Glaxo Welcome HB rapid test(GWHB) with ELISAin sero-assay of HBsAg
=Assay of sera of HBsAg positive patients for HBeAg and anti-HBe HBsAg.
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Table 2:
ELISA- Enzyme Linked Immunoassay
GWHB - Glaxo Welcome HB rapid test
PPV- Positive Predictive Value
NPV- Negative Predictive Value
Table 3:
Parenthesis -percentage
Assay of HBsAg by GWHB and ELISAin 25 Nigerian adults patients.































Male 34(8 1) 7(1 7) 21(50 )
Femalle 8 (19) 1(2) 6(14)
Total 42(1 00) 8(1 9) 27(64 )
Pattern o f Serolo gical M arkers
HBsAg HBeAg Anti-HBe Total
+ve + ve -ve 2 (5)
+ve +ve +ve 6 (14)
+v e - ve +ve 21(50)
+ve - ve -ve 13(31)
Total (1 00) (19) (64 ) 42(10 0)
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Table 5:
A. Determination of HBsAg sero-status by ELISA.
B. Determination of infectivity status of those who
are HBsAg sero-positive by assay of HBeAg,
anti-HBe and HBV DNA polymerase chain
reaction ( detection of HBV pre-core mutants).
This may require antiviral therapy if chronic B.
C. Determination of co-infection(s) - anti-HCV, anti-
HDV and anti- HIV- I & II by ELISA in those
who are with chronic B.
D. Determination of presence of anti-HCV, anti-
HDV and anti- HIV- I & II by ELISA in HBsAg
sero-negative blood for donation.
E. Determination of the presence of antibody to
hepatitis B core antigen (IgM & IgG anti-HBc)
and antibody to HBsAg (anti-HBs) in HBsAg
sero-negative subjects in order to detect those
that will require immunization against HBV
(anti-HBc sero-negative subjects).
F. 6-monthly monitor of subjects who are only
HBsAg sero-positive (HBsAg carrier) for sero-
conversion to anti-HBs or amplification of the
disease by presence of HBeAg, anti-HBe and / or
HBV DNA.
Generally, most of the assays for HBsAg status are
carried out by HMA in resource poor populations
such as Nigeria because of its simple technology,
availability and cheaper cost. Screening for HBV
infection is particularly important when there is need
for blood transfusion, immunization against the
infection, determination of occupational risk
exposure and involvement in some medical
procedures or treatment. Furthermore, many patients
present in the hospital with HBsAg sero-positive
results with mixed feelings, worries and uncertainty
about the consequences. Apart from the heavy work
Algorythm for the serological diagnosis of
HBV infection among Nigerians.
DISCUSSION
load that this would present on medical personnel,
absenteeism from work by patients, the socioeconomic
and emotional burden of a positive report on the patient
and the relations is enormous.Amelioration of this burden
is by eliminating false results through the use of other
more sensitive and specific methods of assaying HBsAg
such as the ELISA, radio-immunoassay tests - RIAand the
gold standard - viral DNA studies. Our study showed that
HMAhad a negative predictive value of 56% (indicating a
high false negative result) when compared with the
ELISA method for the detection of HBsAg. This report
corroborates previous comparison of the two methods that
HM gives false positive results . Declaring false positive
results by HM to patients would cause unnecessary fear to
the ignorant and innocent patients, an unpalatable
situation that could be avoided if only the patients had
been retested by ELISA. In addition, false HBsAg sero-
negative results by HM (compared to ELISA) in 25.5% of
Nigerian adults is highly significant . Informing an
infected healthy adult as uninfected (and vice versa), has
8
9
serious medico-legal implications. The high percentage of
false results of HBsAg status (positive -5.5% and negative
- 25.5%) of about 31% among Nigerians by HMA
compared with ELISA is a clear indication that there is no
further justification for using only HMAin screening blood
for HBsAg prior medical treatment. This calls for an urgent
action by the various sections of the Ministry of health in
the local, state and federal levels of Nigerian government
to make available to all Blood Bank Units the necessary
equipment and wares needed for regular screening of all
donated blood for HBsAg by using a better method such as
ELISA. This will provide a safer blood transfusion service
in the nation and reduce significantly the spread of HBV
infection. In addition, management of the infection among
Nigerians should never be dependent on screening for
HBsAg only by HMA but by ELISA. The second study
showed that GWHB is comparable to ELISA in the
detection of HBsAg in Nigerian subjects, however, the
presence of false sero-negative rate of 20% by the former
calls for a parallel routine test by ELISA in those requiring
the rapid test. GWHB seems rather poor in the detection of
HBeAg status when compared with ELISA. Our result is
however lower than the HBeAg rate of 10.8% obtained in a
previous study among Nigerian HBsAg sero-positive
blood donors and is unlike the result from our study group
with chronic hepatitis. The findings reinforce the need to
screen all patients with ELISA or other tests such as RIA
and polymerase chain reaction for HBV DNA assay in
order to identify subjects that may require anti-viral
therapy.
Nigeria being an endemic nation for HBV infection, the
carriage of the infection occurs among the various age
groups of the population particularly the adults where it
predominate among the 21-30 year group as documented
in the Americans . However, he presence of our subjects
with HBsAg sero-positivity in all the age groups and the
higher proportion of male gender among them is similar to
earlier reports among Nigerians . However, the
preponderance of the infection among the reproductive and
workforce of the nation re-emphasizes the importance of
accurate diagnosis of the infection by highly sensitive and
specific assay methods in order to eradicate its reservoir
through effective treatment of infected subjects. The
detection rate of HBeAg in our subjects is lower than the
value of 45% obtained among similar group of Indian
subjects studied by Chandra et al but similar to the value
of 11.9% reported among Nigerians with chronic liver
diseases . In contrast, the anti-HBe detection rate of 64% in
our subjects (first report among Nigerians) is similar to
53% reported among the Indian subjects .
The high percentage of our subjects with chronic HBV
infection who are either HBeAg or anti-HBe sero-positive
shows that majority of them are respectively of high or low
level of infectivity for HBV. This could be the reason for
the endemic nature of the infection among Nigerian
population of whom were the patients. This situation is
further worsened because the subjects who were sero-
negative for HBeAg but anti-HBe positive, could be
carrying HBV pre-core mutant and thus are negative
secretors of HBeAg . Hence, there is the need for the
definition of actual presence of the HBV pre-core mutant
among Nigerian subjects by HBV DNA studies. From the
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ELISA has become imperative among Nigerians in order
to determine the National burden of the infection so as to
ensure effective management and planning in combating
the HBV endemicity. An algorithm for the serological
diagnosis and treatment of HBV infection among
Nigerians as shown in table 5 is hereby suggested.
In conclusion, our studies have shown that serological
diagnosis of HBV infection is best carried out by ELISA
rather than by the HMA method. Furthermore, though
GWHB is comparable to ELISA in the assay of HBsAg
during emergency situations, a parallel assay by ELISA
will be needed to detect false sero-negative result. GWHB
seems to be poor in the detection of the infectivity status of
HBsAg sero-positive subjects; hence these patients
should be further assessed for HBeAg and anti-HBe by
ELISA technique. In addition, HBV infectivity is high
among adult Nigerian subjects with HBV infection and
would demands accurate diagnosis of the infection among
Nigerian population in order to ensure its effective
treatment and prevention
We are grateful to GSK Pharmaceutical of West Africa,
Lagos, Nigeria; for the donation of GlaxoWellcome
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Bamgboye, Department of Medical Statistics &
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